Benjamin Hohl sold $264k of ELVN
CHIEF FINANCIAL OFFICER at Enliven Therapeutics, Inc.. 6,018 shares at an average of $43.80, traded Jun 17, 2026, filed Jun 22, 2026.
Score components
- +22RoleCFO
- +13Trade size$264k at market
- +5Share of holdings soldSold 11% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001882764-26-000005, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jun 17, 2026 | MOption exercise Common Stock10b5-1 | +6,018 | $2.48 | $15k | 57,018 | Jun 22, 2026 |
| Jun 17, 2026 | SOpen-market sale Common Stock10b5-1 | -1,379 | $42.79 | $59k | 55,639 | Jun 22, 2026 |
| Jun 17, 2026 | SOpen-market sale Common Stock10b5-1 | -3,401 | $43.86 | $149k | 52,238 | Jun 22, 2026 |
| Jun 17, 2026 | SOpen-market sale Common Stock10b5-1 | -1,238 | $44.75 | $55k | 51,000 | Jun 22, 2026 |
| Jun 17, 2026 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -6,018 | $0.00 | $0 | 86,038 | Jun 22, 2026 |
Related signals
Other insiders at Enliven Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 54Moderate | Enliven Therapeutics, Inc. | J. Scott Garland director | $607k 13,000 shares | -100% | |
| 13Weak | Enliven Therapeutics, Inc. | Helen Louise Collins CHIEF MEDICAL OFFICER | $252k 5,000 shares | -17% | |
| 21Weak | Enliven Therapeutics, Inc. | Benjamin Hohl CHIEF FINANCIAL OFFICER | $303k 6,018 shares | -14% | |
| 14Weak | Enliven Therapeutics, Inc. | Helen Louise Collins CHIEF MEDICAL OFFICER | $293k 5,000 shares | -17% | |
| 37Weak | Enliven Therapeutics, Inc. | Benjamin Hohl CHIEF FINANCIAL OFFICER | $353k 6,018 shares | -13% | |
| 40Moderate | Enliven Therapeutics, Inc. | Mika K Derynck director | $9.6M 158,795 shares | -100% | |
| 13Weak | Enliven Therapeutics, Inc. | Helen Louise Collins CHIEF MEDICAL OFFICER | $263k 5,000 shares | -17% | |
| 21Weak | Enliven Therapeutics, Inc. | Benjamin Hohl CHIEF FINANCIAL OFFICER | $317k 6,018 shares | -12% | |
| 33Weak | Enliven Therapeutics, Inc. | Lori Anne Kunkel director | $505k 10,000 shares | -19% | |
| 72Notable | Enliven Therapeutics, Inc. | Orbimed Advisors LLC owner | $39M 860,123 shares | -350% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.